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Group 2 innate lymphoid cells (ILC2s) release inter-
leukin-13 (IL-13) during protective immunity to hel-
minth infection and detrimentally during allergy and
asthma. Using two mouse models to deplete ILC2s
in vivo, we demonstrate that T helper 2 (Th2) cell re-
sponses are impaired in the absence of ILC2s. We
show that MHCII-expressing ILC2s interact with anti-
gen-specific T cells to instigate a dialog in which IL-2
production from T cells promotes ILC2 proliferation
and IL-13 production. Deletion of MHCII renders IL-
13-expressing ILC2s incapable of efficiently inducing
Nippostrongylus brasiliensis expulsion. Thus, during
transition to adaptive T cell-mediated immunity, the
ILC2 and T cell crosstalk contributes to their mutual
maintenance, expansion and cytokine production.
This interaction appears to augment dendritic-cell-
induced T cell activation and identifies a previously
unappreciated pathway in the regulation of type-2
immunity.
INTRODUCTION
Group 2 immunity is believed to have evolved to combat para-
sitic helminth infection, but also contributes to wound healing.
These responses are characterized by adaptive T helper 2
(Th2) cells expressing interleukin-4 (IL-4), IL-5, and IL-13, B cells
secreting immunoglobulin E (IgE), eosinophils, and mast cells.
Innate lymphoid cells (ILCs) also play key roles in type-2 re-
sponses by producing high amounts of type-2 cytokines (Moro
et al., 2010; Neill et al., 2010; Price et al., 2010). ILC2s arise
rapidly during helminth challenge, preceding the expansion of
the adaptive Th2 response. This raises the question of whetherILC2s contribute to the initiation, polarization, or potentiation of
adaptive immunity. Unlike type-1 responses, characterized by
Th1 cells expressing interferon-g (IFN-g), where macrophages
and dendritic cells provide the Th1-cell-inducing factor IL-12,
the pathways that elicit and potentiate Th2 cells and type-2
immunity are less well defined. Although IL-4 is a key factor in
Th2 cell differentiation, type-2 immunity continues in its absence,
indicating additional routes of activation (Forbes et al., 2010;
Kopf et al., 1993). IL-25 and IL-33 have been reported to induce
T cell expression of type-2 cytokines, and it is these two epithe-
lium-derived factors that potently induce ILC2s at the initiation of
type-2 immunity (Moro et al., 2010; Neill et al., 2010). A potential
role for ILC2s in influencing the adaptive type-2 response was
indicated in an early report demonstrating that a non-B/non-T
cell population (later called ILC2) was capable of biasing
T cells to a more type-2 phenotype (Fallon et al., 2006). Later,
the transfer of ILC2s into IL-13-deficient mice, which displayed
reduced T cell responses following helminth infection, was
shown to restore Th2 cell responses in vivo (Neill et al., 2010).
More recently, ILC2-produced IL-13 has been linked to the
migration of dendritic cells (DCs) and the support of Th2 cell dif-
ferentiation (Halim et al., 2014).
Previous studies have demonstrated that MHCII-expressing
conventional antigen-presenting DCs play a critical role in gener-
ating type-2 responses (Hammad et al., 2010; Phythian-Adams
et al., 2010). MHCII is also expressed on B cells, plasmacytoid
DCs, and IFN-g-producing killer DCs (IKDCs), though in lower
amounts than on conventional DCs (Chan et al., 2006; Taieb
et al., 2006). More controversial reports advocated a role for ba-
sophils in antigen presentation (Perrigoue et al., 2009; Sokol
et al., 2009; Yoshimoto et al., 2009). However, the generation
of basophil null mice failed to show any major defects in primary
Th2 cell responses (Ohnmacht et al., 2010). Thus, although ba-
sophils express MHCII, the key function of this molecule in their
biology remains to be fully elucidated.
MHCII is expressed on ILC2s and ILC3s (Hepworth et al.,
2013; Neill et al., 2010). MHCII on ILC3s, in the absence of theImmunity 41, 283–295, August 21, 2014 ª2014 The Authors 283
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mediated suppression of intestinal immune responses against
commensal bacteria (Hepworth et al., 2013). However, the role
of MHCII on ILC2s remains to be fully characterized. Here we
introduce two complementary in vivo models for ILC2 depletion
and demonstrate the importance of ILC2s for the efficient devel-
opment of rapid Th2 cell responses during the expulsion of the
parasitic worm Nippostrongylus brasiliensis.
RESULTS
ILC2s Are Required for Efficient Development of Th2
Cells during N. brasiliensis Infection
Wehave shown thatmice lacking the IL-25 receptor fail to induce
ILC2s efficiently duringN. brasiliensis infection. Concurrently, the
impaired Th2 cell responses that were observed in these mice
implied a role for ILC2s in promoting adaptive immunity (Neill
et al., 2010). To define the roles of ILC2s and Th2 cells during a
type-2 immune response, we generated two complementary
mouse models to enable ILC2 ablation during helminth infection.
First, we generated a mouse strain in which ILC2s can be
depleted temporally by the administration of diphtheria toxin
(DTx). As inducible T cell costimulator (ICOS) is expressed pref-
erentially on both T cells and ILC2s, we inserted a floxed DTx re-
ceptor (DTR) gene into the Icos locus (resulting in a null allele)
enabling the CD4-cre-mediated excision of the DTR gene from
T cells but its retention in ILC2s (see Figures S1A–S1C available
online). Thus, the treatment of inducible ICOS-diphtheria toxin
receptor (iCOS-T) mice with DTx allowed us to selectively
deplete ILC2s while sparing T cells (Figures 1A and 1B).
After N. brasiliensis infection and DTx treatment, we observed
a higher worm burden at day 5 after infection in ILC2-depleted
iCOS-T mice compared to controls (Figure 1C), correlating with
the specific depletion of ILC2s (Figure 1D), but maintenance of
other cell populations (Figures S1H and S1I). Notably, we also
observed that ILC2-depleted iCOS-T mice exhibited a sub-
stantial decrease in IL-5- and IL-13-producing CD4+ T cells (Fig-
ure 1E). Because this deficit primarily affected ICOS+CD4+
T cells, we explored the possibility that ICOS haploinsufficiency
might affect CD4+ T cell function. ICOS expression on CD4+
T cells from iCOS-T mice was reduced as compared to controls
(Figure S1D), but T cell-intrinsic defects were not observed
following IL-33 administration or N. brasiliensis infection (Figures
S1E and S1F). The impaired Th2 cell response might be
explained through an off-target effect of DTx on ICOS+CD4+
T cells. While restimulation of ovalbumin-primed splenocytes
in vitro in the presence of DTx suggested that this was unlikely
(Figure S1G), we generated another strain of ILC2-deficient
mice and repeated the infection studies.
The transcription factor retinoid-related orphan receptor alpha
(RORa) is critical for ILC2 development (Wong et al., 2012). We
have established a conditionally targeted Rorafl/sg mouse that
when intercrossed with IL-7 receptor (IL-7R)-cre (restricted to
the lymphoid lineage) mice yields an ILC2-deficient mouse
strain in which other lineages are unaffected (Figures S2A–
S2C). Rorafl/sgIl7rCre ILC2-deficient mice were infected with
N. brasiliensis and cytokine expression was determined after
5 days. Although we observed little difference in worm burden
at day 5 compared to controls (Figure 1F), this strain does show284 Immunity 41, 283–295, August 21, 2014 ª2014 The Authorsdelayed worm expulsion (Figure S2D). The Rorafl/sgIl7rCre ILC2-
deficient mice had reduced ILC2s (Figure 1G) and a dramatic
deficit in IL-5 and IL-13-producing ICOS+CD4+ T cells (Figure 1H).
Thus, in two distinct ILC2-deficient mouse strains in which
ILC2 ablation is accomplished through discrete pathways, we
observed concordant in vivo defects in CD4+ Th2 cells. These
data support an in vivo interplay between ILC2s and CD4+
T cells, and we proceeded to investigate the potential role of
ILC2-expressed MHCII in this interaction.
MHCII Is Expressed, but Also Acquired, by ILC2s
We confirmed MHCII expression on 50%–70% of naive wild-
type (WT) ILC2s (Lin–Klrg1+CD25+ST2+ICOS+Sca1hiGATA3+IL-
13+) and those elicited in response to IL-25 or IL-33, as
compared to ILC2s from MHCII-deficient mice (H2-Ab1/,
referred to throughout as MhcII/) (Figure 2A and 2B; Figures
S3A–S3C). Expression of MHCII on ILC2s was at lower amounts
than that on B cells (Figure 2C). Lymph node, spleen, and Peyer’s
patch-derived ILC2s expressed MHCII, but ILC2s from the peri-
toneal lavage, bronchoalveolar lavage, and lung had consider-
ably lower frequency ofMHCII expression (Figure 2C; Figure S3D
and S3E). A proportion of ILC2s also expressed the costimula-
tory molecule CD80 and to a lesser extent CD86 (Figure 2D),
which are required, in combination with MHCII, for T cell activa-
tion and survival. Thus ILC2s express MHCII on their surface and
have the potential to interact directly with CD4+ T cells via this
molecule.
ILC2 culture, for as little as 2 days, resulted in loss of cell sur-
face expression of MHCII and by day 6 of culture only 10% of
ILC2s retained MHCII expression (Figure 2E; Figure S3F). An-
nexin V staining confirmed that this was not due to selective
apoptosis of MHCII+ cells (Figure 2F), raising the possibility
that the presence of MHCII on ILC2s might arise through trogo-
cytosis from antigen-presenting cells (APCs) (Wetzel et al., 2005)
and that its loss from ILC2swas the result of membrane turnover.
Trogocytosis of MHCII by ILC2s was assessed by generating
mixed bone-marrow chimeras using CD45.1+ WT and CD45.2+
MHCII-deficient cells. Low amounts of MHCII dressing were de-
tected on the ILC2s originating from the MHCII-deficient bone
marrow, and this was equivalent to the amount of MHCII acqui-
sition observed on other populations, including B cells (Fig-
ure 2G; Figure S3G). Cross-dressing did not account for all
MHCII on the surface of ILC2s and, furthermore, ILC2s
(confirmed as GATA3+ and CD11c– compared to DC popula-
tions; Figure S3H) expressed mRNA encoding H2-Aa, H2-Ab1,
and H2-Eb1, invariant MHCII chaperone CD74, and the MHC
transcriptional activator CIITA (Figure 2H). Notably, downregula-
tion of these MHC-related genes coincided with the loss of cell
surface MHCII following in vitro culture. Thus, ILC2s express
endogenous MHCII and might also acquire this molecule by
trogocytosis.
ILC2 Expression of MHCII Is Important for the
IL-13-Dependent Expulsion of N. brasiliensis
To investigate the biological importance of MHCII expression by
ILC2s in vivo, we assessed the effect of deleting MHCII from
ILC2s during an N. brasiliensis worm infection. Resolution of
N. brasiliensis infection is highly dependent on ILC2s, which pro-
vide the IL-13 that induces the intestinal mucus production and
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Figure 1. ILC2 Ablation Leads to Impaired Th2 Responses to N. brasiliensis
(A) ILC2 ablation. Representative flow cytometric analysis of MLN from WT, iCOS-DTR (without Cd4Cre), or iCOS-T mice (with Cd4Cre), treated with three daily
doses of DTx (25 ng/g bodyweight) and IL-33.
(B) Numbers of T cells and ILC2s in MLN of mice, treated daily with 3 doses of DTx and IL-33.
(C) Worm burden in mice at 5 days postinfection (d.p.i). iCOS-T mice treated daily with DTx (15 ng/g bodyweight, i.p.).
(D) ILC2s in mice 5 d.p.i.
(E) CD4+ T cells producing IL-5 and IL-13. Statistical analysis performed between CD4+ICOS+ T cell populations (black bars).
(F) Worm burden in Rorafl/sgIl7rCre mice 5 d.p.i.
(G) ILC2 numbers in Rorafl/sgIl7rCre mice 5 d.p.i.
(H) CD4+ T cells producing IL-5 and IL-13. Statistical analysis performed between CD4+ICOS+ T cell populations (black bars).
Data are representative of at least two independent experiments with three (A and B) or five (C–H) mice per group and bar graphs representmean ± SEM. *p < 0.05
and ** < 0.001. See also Figures S1 and S2.
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ILC2:T Cell Dialogue Potentiates Type-2 Immunitymuscular contraction characteristic of the ‘‘weep and sweep’’
response (Fallon et al., 2002). IL-13-deficient hosts (in which
the Il13 gene has been replaced with the eGFP gene [Neill
et al., 2010]) are impaired in their ability to expel N. brasiliensis,
but parasite clearance can be rescued by transferring WT
IL-13-sufficient ILC2s into these hosts.
We tested the function of MHCII expression on ILC2s by trans-
ferring MHCII-deficient ILC2s into the N. brasiliensis-infected IL-13-deficient mice. The transferred ILC2s could be identified in
the IL-13-deficient recipients due to expression of IL-13 protein
(Figure S4A). Despite having similar intestinal parasite burdens at
day 4/5, only IL-13-deficient hosts receiving WT ILC2s expelled
their worms efficiently by day 7 (Figure 3A). By contrast, IL-13-
deficient hosts receiving MHCII-deficient ILC2s displayed de-
layed parasite expulsion (Figure 3A). Notably, IL-13-deficient
hosts receiving MHCII-deficient ILC2s showed impaired wormImmunity 41, 283–295, August 21, 2014 ª2014 The Authors 285
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Figure 2. MHCII Is Expressed by ILC2s
(A) Representative flow cytometry of MHCII on ILC2s from the MLN of naive mice. Plots are gated on lin– cells.
(B) MHCII expression by ILC2s from the MLN of mice treated i.p. as indicated. Plots are gated on lin– cells.
(C) MHCII expression on IL-33-elicited ILC2s and B cells from the indicated tissues.
(D) CD80 and CD86 expression on Lin–ICOS+ MLN cells from IL-33-treated mice.
(E) MHCII expression on IL-25-elicited ILC2s cultured as indicated.
(legend continued on next page)
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Figure 3. MHCII-Deficient ILC2s Fail to
Rescue N. brasiliensis Expulsion in IL-13-
Deficient Hosts
(A) Worm burden in IL-13-deficient hosts following
transfer of ILC2s from IL-25-treatedWTorMhcII/
donors. Data are pooled from four independent
experiments with five or six mice in each group per
experiment. *p < 0.05, **p < 0.01, and ***p < 0.001.
(B) Number of Il13egfp/egfp CD4+ T cells in MLN
following infection.
Data are representative of three independent ex-
periments with five to six mice per group. Bar
graphs represent mean ± SEM. See also Fig-
ure S4.
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(Figure 3B), presumably driven by endogenous MHCII-sufficient
APCs. Importantly, we found no intrinsic deficit in the ability of
MHCII-deficient ILC2s to produce IL-13 as compared to controls
(Figures S4B and S4C). These results suggest a dialog between
ILC2s and T cells that is required to induce sufficient IL-13-pos-
itive ILC2s.
ILC2 MHCII Contributes to Antigen-Induced Activation
of CD4+ T Cells
We next investigated the potential role for MHCII on ILC2s. Puri-
fied C57Bl/6 ILC2s were cultured with ovalbumin (OVA)-specific
OTII transgenic (Tg) C57Bl/6 CD4+ T cells (Barnden et al., 1998)
in the presence or absence of OVA-derived peptide. ILC2s
induced in vivo with IL-25 or IL-33 and preincubated with OVA-
peptide induced similar T cell proliferation (Figure 4A; Fig-
ure S5A). In contrast, CD4+ T cells alone, or cocultures of
T cells and ILC2s in the absence of OVA peptide, failed to induce
T cell proliferation. ILC2s were purified by flow cytometry to
avoid DC cross-contamination (Figure S5B) and limiting dilution
analysis confirmed that the contribution of contaminating DCs
could be discounted (data not shown). Similar results were ob-
tained with ILC2s purified from BALB/c mice in the presence of
BALB/c DO11.10Tg CD4+ T cells (Figure S5C). An irrelevant pep-
tide derived from myelin proteolipid protein failed to stimulate
DO11.10Tg T cell proliferation (Figure S5D). ILC2s that had
downregulated surface MHCII expression following in vitro cul-
ture (Figure 2E) also failed to stimulate DO11.10Tg T cell proli-
feration (Figure S5E). The inclusion of DCs in these cultures
indicated that in vitro cultured ILC2s did not actively impair
T cell proliferation (Figure S5E). The peptide-presenting capacity
of ILC2swas significantly lower than that of CD11c+ DCs but was
equivalent to that observed for naive B cells, IKDCs, and plasma-
cytoid DCs (Figure 4B).
Unlike ILC2s from WT mice, MHCII-deficient ILC2s failed to
induce OTIITg T cell proliferation (Figure 4C). To confirm that
the absence of MHCII had not altered the developmental state(F) Annexin V and MHCII expression on IL-33-elicited lymph node ILC2s cultured
(G) Chimeric mice were generated by mixing B6SJL (CD45.1+) bone marrow w
expression was determined following three doses of IL-33 (i.p.). Graph shows m
(H) Quantitative RT-PCR for MHCII (H2-Aa, H2-Ab1, or H2-Eb1), Cd74 and Ciita
IL-33-treated mice.
Data are representative of at least two independent experiments with three miceof ILC2s in the MHCII gene-targeted mice, we also demon-
strated that a neutralizing anti-MHCII antibody, but not an iso-
type control, prevented proliferation of OTIITg T cells cocultured
with peptide-pulsed ILC2s (Figures 4D and 4E; Figure S5F). An-
tigen-dependent T cell activation by ILC2swas further confirmed
by increased numbers of activated CD4+ T cells (CD44+CD69+
CD62L, Figures 4F and 4G). These data demonstrate that
ILC2 MHCII ligation induced the expansion and activation of
CD4+ T cells.
Because ILC2s express the costimulatory molecules CD80
and CD86 (Figure 2D), we examined the role for these molecules
by using blocking antibodies in vitro. Although individual
blockade of CD80 or CD86 had little effect on T cell proliferation
(Figure 4H), a combination of both antibodies inhibited T cell
proliferation as compared to controls (Figure 4H). Antibody
blocking was ineffective in BALB/c DO11.10Tg cocultures
(data not shown), suggesting potential effects of TCR affinity
on the requirement for costimulatory signals. Thus, the expres-
sion of the costimulatory molecules CD80 and CD86 by ILC2s
provides an additional signal for the proliferation of OTIITg
T cells in the context of peptide.
Murine ILC2s Endocytose, Process, and
Present Antigen
ILC2s endocytosed soluble antigen in vitro dose dependently
(Figures S5G–S5I) and also degraded ovalbumin-DQ (OVA-
DQ), a self-quenched conjugate of ovalbumin protein that fluo-
resces when cleaved (Figures S5H and S5I). Furthermore, in vivo
processed OVA-DQ fluorescence was observed in bronchoal-
veolar lavage and lung-derived ILC2s following intranasal anti-
gen administration (Figures S5J and S5K). However, neither
ILC2s loaded in vitro with OVA, or sorted OVA-DQ-positive
ILC2s, loaded in vivo, induced transgenic T cell proliferation in
coculture (Figures S5L and S5M). To determine whether this re-
sulted from an inability of ILC2s to present the processed anti-
gen, we cultured ILC2s in the presence of an E-alpha (Ea)-green
fluorescent protein (GFP) fusion protein and used an Ea-specificfor 48 hr.
ith either C57Bl/6 or MhcII/ bone marrow (CD45.2+) in a 1:1 ratio. MHCII
ean fluorescence intensity (MFI) of MHCII expression by ILC2s.
gene expression from the indicated populations. ILC2s are from the MLN of
per group. Bar graphs represent mean ± SEM. See also Figure S3.
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ILC2:T Cell Dialogue Potentiates Type-2 Immunityantibody to detect an Ea-derived peptide bound in the context of
MHC (I-Ab) (Pape et al., 2007). ILC2s were incubated with
Ea-GFP and after 20 hr stained for the presence of Ea-derived
peptide. Notably, a proportion of theWT, but not MHC-deficient,
ILC2s stained positive for the presence ofMHCII-bound Ea-pep-
tide as did DCs and B cells (Figure 4I). Thus, ILC2s can process
and present antigen, albeit to a lesser extent than professional
APCs, but not sufficiently to elicit T cell proliferation in the
in vitro assays tested.
ILC2s Enter an Antigen-Dependent Dialog with
CD4+ T Cells
We next examined whether ILC2s polarize OTIITg CD4+ T cells
toward a Th2 phenotype. Supernatants from OTIITg T cells
cocultured with OVA peptide-pulsed ILC2s contained markedly
increased amounts of type-2 cytokines IL-5, IL-6, IL-9, and
IL-13, but little IFN-g or IL-17A, as compared to controls lacking
peptide (Figure 5A; Figure S6A). This elicitation of type-2 cyto-
kine expression was blocked by neutralizing anti-MHCII anti-
body (Figure 5A). Notably, this antigen- and MHCII-dependent
increase in type-2 cytokines correlated with enhanced ILC2
numbers (Figure 5B).
The source of type-2 cytokines was investigated with cocul-
tures containing either WT ILC2s or ILC2s harvested from mice
with a combined deficiency for IL-4, IL-5, IL-9, and IL-13
(QUAD-KO) (Fallon et al., 2002). Coculture of WT ILC2s and
DO11.10Tg T cells resulted in IL-5 and IL-13 expression that
increased with the inclusion of peptide (Figure 5C). Comparison
to parallel cultures, in which QUAD-KO ILC2s were combined
with transgenic T cells, demonstrated that the majority of the
IL-5 and IL-13 observed in the WT cultures was ILC2-derived
(Figure 5C) and that type-2 cytokine production was only
induced in T cells following the addition of peptide (Figure 5C).
The absence of ILC2-derived type-2 cytokines had no effect
on the proliferative potential of T cells (Figure 5D). Intracellular
cytokine staining confirmed that ILC2s were the major source
of type-2 cytokines following coculture in the presence of OVA
peptide (Figure 5E; Figure S6B). Blocking antibodies targeting
MHCII (Figure 5E; Figure S6B) or CD80 and CD86 (Figures 5F
and 5G) impaired ILC2 expansion and type-2 cytokine expres-
sion. Together, these data highlight that ILC2s and T cells enter
an antigen-dependent crosstalk that results in their subsequent
activation and potentiation of type-2 immune responses and re-
quires the expression of both MHCII and the costimulatory mol-
ecules CD80 and CD86 on ILC2s.
Crosstalk between ILC2s andCD4+ TCells Requires IL-2
We next sought to identify the secreted factors required for
ILC2s and CD4+ T cell interaction. Notably, although IL-4, aFigure 4. Antigen-Dependent Activation of T Cells by ILC2s Requires M
(A) Cell trace violet (CTV)-labeled OTIITg CD4+ T cells were cultured in a 1:1 ratio
(B) Antigen-dependent OTIITg CD4+ T cell proliferation induced by the indicated
(C) CFSE-labeled OTIITg CD4+ T cell proliferation, as indicated.
(D) CTV-labeled OTIITg CD4+ T cell proliferation, as indicated.
(E) OTIITg CD4+ T cell numbers in cocultures, as indicated.
(F and G) The number of activated OTIITg CD4+ T cells (CD44+CD69+ or CD44+C
(H) CTV-labeled OTIITg CD4+ T cell proliferation, as indicated. Data are represen
(I) Detection of processed and presented Ea peptide on ILC2s. Data are represe
ILC2s were elicited using IL-33 and isolated from mesenteric, para-aortic, and infactor linked to Th2 cell polarization, is not always detectable
in ILC2s (Fallon et al., 2006; Neill et al., 2010), we observed
that IL-4 production from ILC2s was clearly evident in the pres-
ence of peptide (Figure 5C; Figures S6B and S6C). Blocking IL-4
in cocultures had only a small effect on IL-13+ ILC2 and T cell
numbers (Figures 6A and 6B). Thus, IL-4 might play a minor
role in altering the cytokine milieu that arises in the MHCII-medi-
ated collaboration between ILC2s and T cells.
The limited effect of IL-4 led us to investigate IL-2, the receptor
for which (CD25) is highly expressed on ILC2s. Indeed, culture of
ILC2s with IL-2 resulted in increased numbers of IL-13-produc-
ing ILC2s (Figure 6C). Intracellular cytokine staining demon-
strated an antigen-dependent increase in the number of IL-2-
expressing T cells in ILC2 cocultures, which was impaired with
anti-MHCII antibodies (Figures 6D and 6E). Critically, IL-2
blockade prevented antigen-induced expression of type-2 cyto-
kines in culture supernatants (Figure 6F), and intracellular cyto-
kine staining confirmed a role for IL-2 in the expression of
type-2 cytokines from ILC2s (Figure 6G) and T cells (Figure 6H).
We have shown previously that Rag2/ mice have impaired
worm clearance. To determine whether this deficit might be
due to insufficient IL-2 production from T cells failing to induce
sufficient ILC2s, we infected Rag2/ mice with N. brasiliensis
while also treating one group with an IL-2-anti-IL-2 antibody
complex to facilitate slow release of the active IL-2 molecule.
Rag2/mice sufficient for ILC2s failed to expel their worms effi-
ciently (Figure 6I). By contrast, providing IL-2 resulted in rapid
worm expulsion that correlated with elevated ILC2 numbers (Fig-
ures 6I and 6J). Thus, theMHCII-, CD80-, CD86-initiated produc-
tion of IL-4 and IL-2 from ILC2s and T cells coordinates efficient
T cell and ILC2 proliferation and type-2 cytokine expression.
Human ILC2s Express MHCII and Present Antigen
to T Cells
In parallel studies, we assessed MHCII expression on purified
human lineage–IL-7Ra+CRTH2+ ILC2s (Mjo¨sberg et al., 2011;
Salimi et al., 2013) (Figure S6D). Human ILC2s expressed high
amounts of HLA-DR, comparable to human monocytes, in
conjunction with the costimulatory receptors CD80 and CD86
(Figure S6E). We investigated the ability of human ILC2s to acti-
vate human T cell lines with antigen specificity for the common
house dust-mite allergen (HDM) Der p 1. Increasing concentra-
tions of whole Der p 1 protein or Der p 1 peptide (DRB15),
induced a 100- to 200-fold increase in the expression of IL-4 (Fig-
ure S6F), accompanied by a 3-fold increase in IFN-g production
(Figure S6G). Intracellular cytokine staining revealed induction of
T cell-derived IL-13 in HLA-DR+ ILC2 cocultures, but not those
with anti-MHCII or HLA-mismatched ILC2s (Figure S6H). How-
ever, ILC2-produced IL-13 was not detected (Figure S6H).HCII
with IL-33-elicited ILC2s, pulsed with or without OVA-peptide.
populations.
D62L–) following coculture with antigen-pulsed ILC2s.
tative of three independent experiments with two or three mice per group.
ntative of two independent experiments.
guinal lymph nodes. Bar graphs represent mean ± SEM. See also Figure S5.
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Figure 5. ILC2s Enter Antigen-Dependent Dialog with CD4+ T Cells
(A) Cytokines in supernatants of cocultures containing peptide-pulsed ILC2s and OTIITg CD4+ T cells. Dotted line indicates limit of detection for each assay.
(B) ILC2 number following coculture with OTIITg CD4+ T cells, as indicated.
(C) Cytokine production in supernatants of WT (BALB/c) or QUAD-KO ILC2s and DO11.10Tg T cell cocultures, as indicated.
(D) CFSE-labeled DO11.10Tg T cell proliferation following coculture with QUAD-KO ILC2s, as indicated.
(E) Intracellular IL-13 staining following ILC2:OTIITg CD4+ T cell coculture, as indicated.
(legend continued on next page)
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ILC2:T Cell Dialogue Potentiates Type-2 ImmunityThus, human ILC2s can process and present antigens to T cells
thereby initiating cytokine expression.
DISCUSSION
A critical role for ILC2s in antihelminthic immune responses was
demonstrated in mice deficient in IL-33 and IL-25 signaling (Neill
et al., 2010) and in RORa-deficient mice, which lack ILC2s (Wong
et al., 2012). Transfer of ILC2s into IL-13-deficient, but not Rag2-
deficient, hosts was sufficient to restore worm clearance (Neill
et al., 2010). This suggested that interactions between IL-13-suf-
ficient ILC2s and T cells, but probably not B cells (Voehringer
et al., 2006), were required for the effective clearance of parasitic
helminths. The impairment of T cell responses suggested that in
addition to conventional T cell priming by DCs, which is essential
for efficient Th2 generation (Hammad et al., 2010; Phythian-
Adams et al., 2010), ILC2s might also play a previously unantic-
ipated role in the initiation of protective type-2 immunity.
We have generated two ILC2-depletion models to study ILC2
function in vivo. The iCOS-T model relies upon Icos-promoter
controlled expression of DTR on ILC2s enabling temporal regu-
lation of ILC2 deletion by DTx-administration. In the second
model, ILC2s were depleted through IL-7Rcre-mediated exci-
sion of a ‘‘floxed’’ exon in theRora gene. In these distinct models,
we observed that ILC2 ablation impaired the magnitude of the
Th2 response during N. brasiliensis infection.
While MHCII-expressing conventional antigen-presenting
DCs are essential for activating naive T cell responses (Hammad
et al., 2010; Phythian-Adams et al., 2010), MHCII-mediated
crosstalk between ILC2s and T cells plays an additional role in
potentiating IL-13-dependent N. brasiliensis expulsion. T cell-
derived IL-2 induces proliferation of ILC2s and elevates their
expression of type-2 cytokines. Thus, this reciprocal interaction
potentiates both the innate and adaptive sources of type-2 cyto-
kines and provides an important antigen-dependent feedback,
whereby regulation of ILC2 proliferation or survival shifts from
innate sources of IL-33 and/or IL-25 (Neill et al., 2010) to cyto-
kines provided by an ongoing adaptive response, namely IL-2
and IL-4 derived from T cells.
Several pathways regulate Th2 cell differentiation, including
TCR signal strength, ligation of costimulatory molecules on
APCs, and availability of cytokines such as IL-2 and IL-4 (Cote-
Sierra et al., 2004; Jenkins et al., 2008; Yamane et al., 2005).
Coculture of T cells with ILC2s, in the presence of antigen, pref-
erentially induces T cell secretion of IL-5 and IL-13. Notably, we
observed relatively low amounts of MHCII expression on ILC2s,
compared to DC subsets or B cells. This interaction might
contribute to the polarization of the T cell response because sub-
optimal TCR ligation has been reported to bias Th2 differentia-
tion in vitro (Yamane et al., 2005) and in vivo (Jun et al., 2003).
Similarly, components from Schistosoma mansoni egg extracts
have been demonstrated to condition DCs, resulting in their
impaired interaction with T cells and potentially reduced TCR
signal strength (Everts et al., 2009). Therefore, ILC2s, unlike(F) ILC2 number following coculture with OTIITg CD4+ T cells, as indicated.
(G) Intracellular IL-13 staining following ILC2:OTIITg CD4+ T cell coculture, as ind
Data are representative of three independent experimentswith two or threemice p
graphs represent mean ± SEM. See also Figure S6.other APC, might be preconditioned to polarize T cells toward
a Th2 phenotype by virtue of their lower amount of MHCII
expression.
Cytokine regulation of Th2 cell differentiation has focused on
IL-4 though it is clear that it is not essential for Th2 development
in vivo (van Panhuys et al., 2008). Indeed, we found little role for
IL-4 in the ILC2-regulated differentiation of Th2 cells. By
contrast, IL-2 was critical for the proliferation of Th2 cells in the
presence of ILC2s and antigen. IL-2 is expressed by T cells
following CD28 ligation (Seder et al., 1994) and plays an impor-
tant role in Th2 differentiation via STAT5a signaling (Cote-Sierra
et al., 2004; Zhu et al., 2003). Notably, we found that the CD28
ligands CD80 and CD86 were expressed on ILC2, suggesting
that ILC2s have the capacity to interact with T cells and
contribute to their type-2 polarization.
Strikingly, we observed a profound increase in ILC2 prolifera-
tion and type-2 cytokine production in T cell cocultures with an-
tigen, which was dependent on T cell-derived IL-2. ILC2s require
the common g-chain (gc) receptor for their development and
proliferation, and are absent in gc receptor-deficient mice
(Moro et al., 2010; Neill et al., 2010; Price et al., 2010). Further-
more, Moro et al. (2010) showed that ILC2s from fat-associated
lymphoid clusters (FALC) expanded in the presence of IL-2, re-
sulting in elevated amounts of cytokine production (Moro et al.,
2010). Additionally, IL-2 has also been reported to induce
ILC2s to secrete IL-9, which then protects the ILC2s from
apoptosis via an autocrine feedback loop (Turner et al., 2013).
Therefore, it is possible that IL-2 expressed following antigen-
dependent ILC2:T cell interactions induces IL-9 expression
and improves ILC2 survival, thereby further biasing toward a
type-2 immune response. Certainly, IL-9 was present in the cul-
tures that included T cells and antigen, thoughwewere unable to
identify the cellular source.
Despite demonstrating that murine ILC2s can take up and
process OVA, and process and present Ea-GFP, we have
been unable to demonstrate T cell proliferation. Several studies
have shown that cells can acquire MHCII:antigen complexes
from antigen-presenting cells (Wetzel et al., 2005). We observed
acquisition of MHCII by ILC2s in mixed bone-marrow chimera
experiments, which might contribute to their biology. How-
ever, where MHCII-deficient ILC2s were transferred into
N. brasiliensis-infected MHCII-sufficient mice, MHCII trogocyto-
sis was insufficient to restore worm expulsion. In contrast to
mouse ILC2s, we found that human ILC2s process whole Der
p 1 antigen and present the derived peptides to T cells in vitro.
Thus, our existing in vitro cellular proliferation assays appear
too insensitive. Previously, human NK cells have been shown
to process and present tetanus toxoid and Der p 1 to T cells,
but protein antigen from Mycobacterium leprae was poorly pro-
cessed and presented (Roncarolo et al., 1991). It is also note-
worthy that many of the antigens associated with type-2 immune
responses are either shed by multicellular helminth parasites
(Kamata et al., 1995) or are proteins with protease activity,
such as Der p 1 or papain (Gough et al., 1999; Halim et al.,icated.
er group.MLN ILC2swere elicited using IL-33 (A, B, E–G) or IL-25 (C andD). Bar
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ILC2:T Cell Dialogue Potentiates Type-2 Immunity2012). It is therefore interesting to speculate that ILC2s might
also acquire exogenous peptides from their surroundings (San-
tambrogio et al., 1999).
This proinflammatory role for MHCII expression on ILC2s sup-
ports similar findings for peptide presentation by ILC2s (Mirch-
andani et al., 2014). By contrast, ILC3s have been reported to
suppress intestinal immune responses against commensal bac-
teria (Hepworth et al., 2013). Notably, ILC2s express the costi-
mulatory molecules CD80 and CD86 on their surface, whereas
ILC3s do not (Hepworth et al., 2013), and this might underlie
the agonistic role for MHCII on ILC2s.
In addition to antihelminthic immunity, ILC2s have also been
implicated in promoting detrimental type-2 immune responses
in mouse models of asthma (Barlow et al., 2012; Chang et al.,
2011; Monticelli et al., 2011) and allergies (Bartemes et al.,
2012; Halim et al., 2012; Salimi et al., 2013). Currently there is
little information regarding ILC2s and T cell interactions in
allergic models, but similar antigen-dependent ILC2:T cell
crosstalk might also be important for the potentiation of type-
2 responses in allergy. Indeed, ILC2s are enriched in nasal
polyps from patients with chronic rhinosinusitis (Mjo¨sberg
et al., 2011), which might arise in response to allergens. We
have now demonstrated the ability of human ILC2s to process
and present the house-dust-mite allergen Der p 1, to human
T cells in vitro in a process that would exacerbate type-2 inflam-
mation. In these human assays, we observed the induction of
T cell-derived IL-13, but did not detect ILC2-produced IL-13.
It is not clear why this is the case but might be a consequence
of the 3- to 4-week culture required to derive sufficient ILC2s for
these assays. However, these data support a potential role for
human ILC2s in the potentiation of T cell responses during
asthma and allergy.
The two mouse models that we describe for the genetic abla-
tion of ILC2s in vivo complement those that have already been
reported. The use of the Il13 gene to drive diphtheria toxin re-
sulted in the deletion of IL-13-producing ILC2s, but other IL-
13-producers would also be susceptible to toxin-mediated cell
death (Liang et al., 2012). The depletion of ILC2s has also been
reported in mice in which Id2CreER mediated the excision of a
conditional Gata3 allele (Hoyler et al., 2012); however, it is
becoming clear that GATA3 is required for all ILC populations
(Serafini et al., 2014). We now show that ILC2 ablation can be
regulated temporally in otherwise immune-competent iCOS-T
mice. Because it remained possible that the insertion of DTR
into the Icos locusmight alter T cell activation, we also generated
Rorafl/sgIl7rCre mice. Although RORa has been reported previ-
ously to play a subordinate role to RORg in the development of
Th17 T cells, a role in Th2 cell activation has not been reported.Figure 6. IL-2 Is Required for the Antigen-Dependent Dialog between
(A and B) Number of IL-13-expressing ILC2s (A) and T cells (B) from ILC2:OTIITg
(C) Surface CD25 and intracellular IL-13 expression by ILC2s stimulated with IL-
(D) Intracellular IL-2 staining of CTV-labeled OTIITg CD4+ T cells following cocul
(E) Number of IL-2-expressing T cells from ILC2:OTIITg CD4+ T cell cocultures in
(F) IL-13 concentration in supernatants from ILC2:OTIITg CD4+ T cell cocultures
(G and H) Number of cytokine expressing ILC2s (G) and OTIITg CD4+ T cells (H)
(I) Worm burdens and (J) ILC2s in Rag2/ mice 10 d.p.i. with N. brasiliensis and
Lymph node ILC2s were elicited with IL-33. Bar graphs represent mean ± SEM. D
per group (A–H) or from a single experiment with five or six mice per group (I andThus, the complementary data from these two distinct mouse
lines strongly support the role for ILC2s in the progression to
adaptive Th2-mediated immunity. Thesemice should prove use-
ful for defining the roles of ILC2s in further disease models.
Our data demonstrate that ILC2s and T cells cooperate
through MHCII-dependent activation to potentiate the type-2
response against N. brasiliensis and extend the recently
described pathway by which IL-13 from ILC2s can promote
DCmigration to the draining lymph nodes to stimulate Th2 polar-
ization (Halim et al., 2014). Such functions place ILC2s at a crit-
ical point in the transition from the innate type-2 response to
adaptive type-2 immunity. Therefore, ILC2s expand initially in
response to IL-33 and IL-25 derived from innate cell sources
but require adaptive T cell-produced mediators for their main-
tenance and subsequent potentiation of protective type-2
immunity.
EXPERIMENTAL PROCEDURES
Mice
C57Bl/6, H2-Ab1/ (MhcII/) (Cosgrove et al., 1991), Il13egfp/egfp (Neill et al.,
2010), Il7rCre (Schlenner et al., 2010), OTIITgB6 (JAX Laboratories), and
Staggerer Rorasg/+ (JAX Laboratories) mice were on a C57Bl/6 background.
Il13tdTomato/+, Il4gfp/gfp (Hu-Li et al., 2001) and Il4/Il5/Il9/Il13/
(QUAD-KO) (Fallon et al., 2002) mice were on a BALB/c background. iCOS-
DTR, iCOS-T, and Rora+/floxIl7rCre mice were generated as described in the
Supplemental Experimental Procedures. All mice were bred in a specific path-
ogen-free facility. BALB/c mice were purchased from Charles River Labora-
tories as required. In individual experiments all mice were matched for age,
gender, and background strain. All animal experiments undertaken in this
study were done so with the approval of the UK Home Office.
IL-25, IL-33, IL-2 Complex and DTx Administration
IL-25 (either 2 mg/mouse or 0.5 mg/mouse of recombinant mouse IL-25
[Centocor] in PBS) was administered daily for 3 days intraperitoneally (i.p.,
termed IL-25-elicited ILC2s). For i.p. IL-33 administration, 0.5 mg/mouse or
1 mg/mouse recombinant mouse IL-33 (BioLegend) in PBS was administered
daily for up to 4 days (termed IL-33-elicited ILC2s). For intranasal IL-33
administrations, mice were anesthetized and 0.4 mg of recombinant protein
administered in PBS on 4 consecutive days. IL-2 complexes were prepared
by incubating IL-2 and anti-IL-2 mAb (clone JES6) (both from R&D Systems)
at a 1:5 w/w ratio for 20 min at 37C. Complexes were then diluted in PBS
and administered i.p. (1 mg IL-2 and 5 mg anti-IL-2 per dose) on days 0, 2, 4,
6, and 8 following N. brasiliensis infection. DTx (either 25 ng/g or 15 ng/g
body weight, Sigma) was administered daily for up to 5 days i.p. Mice were
euthanized 24 hr later and tissues collected for analysis. Control animals
received PBS only.
Bone-Marrow Chimeras
Formixed-chimera experiments, lethally irradiated CD45.1+ B6/SJLmicewere
reconstitutedwith a 1:1mixture of bone-marrow cells (23 106 cells) containing
either CD45.1+ B6/SJL and CD45.2+ C57Bl/6 or CD45.1+ B6/SJL and CD45.2+ILC2s and T Cells
CD4+ T cell cocultures in the presence of IL-4-blocking antibodies.
2 for 72 hr.
ture with OVA-peptide-loaded WT ILC2s.
the presence of MHCII-blocking antibodies.
in the presence of blocking anti-IL-2 antibodies.
in the presence of IL-2 blocking antibodies.
treated as indicated.
ata are representative of three independent experiments with two or three mice
J). Bar graphs represent mean ± SEM.
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mouse IL-33 (0.4 mg per dose).
In Vitro ILC2 Cultures with IL-7 and IL-33 or IL-2
For the expansion of ILC2s in vitro fromWTmice, ILC2swere FACS purified, as
defined by LIN (a combination of CD3, CD4, CD8a, CD19, B220, CD11c,
CD11b, Gr1, FcεR1, CD5, g/dTCR, NK1.1, and TER119) ICOS+. For IL-7/IL-
33 in vitro cultures of ILC2s, we followed the protocol as described previously
(Neill et al., 2010). Cultures were maintained for between 2 and 6 days. For
in vitro IL-2 cultures, ILC2s were FACS purified from the spleen and MLN of
IL-25 or IL-33-treated mice, and subsequently cultured at 2.5 3 104 cells per
well in the presence or absence of IL-2 (10 ng/ml). Cultures were maintained
for 3 days at 37C.
In Vitro ILC2s and T Cell Cocultures
Freshly isolated or in vitro cultured ILC2s, from WT, MhcII/, or QUAD-KO
mice, were resupended in RPMI 1640 (GIBCO) supplemented with 2 mM
L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, and 10% Hyclone
Fetal Bovine Serum (Thermoscientific). Where necessary, ILC2s were pulsed
with OVA-peptide (323–339) for 2 hr at 37C. Subsequently ILC2s were
washed thoroughly and 1 3 104 ILC2s were cultured with 1 3 104 labeled
CD3+CD4+ OTIITg or DO11.10Tg splenic T cells, which were sorted by
flow cytometry, for 5 days at 37C, 5% CO2. Where indicated, the antibodies
M5/114.15.2 (anti-MHCII, eBioscience), 16-10A1 (anti-CD80, BioLegend),
and GL-1 (anti-CD86, BioLegend) were added to cultures at a concentration
of 1 mg/ml. 11B11 (anti-IL-4, eBioscience) was incubated at a concentration
of 10 mg/ml. Where appropriate, blockade of IL-2 was performed with
10 mg/ml of JES6-1A12 (eBioscience) and S4B6 (BD PharMingen). Cocul-
tures containing in vivo-loaded OVA-DQ+ ILC2s were prepared by FACS-
purifying ILC2s, based on LinICOS+OVA-DQ+ or lineageICOS+OVA-DQ,
from the bronchoalveolar lavage of WT mice receiving an intranasal admin-
istration of OVA-DQ and IL-33 on 7 consecutive days. Cocultures were setup
at a 1:1 ratio with 4 3 104 cells per well. Human samples were taken under
GCP guidance with ethical approval of the NRES Committee South Central.
Helminth Infection and Cell Transfers
Mice were inoculated subcutaneously with 500 viable third-stage
N. brasiliensis larvae. Where appropriate, FACS-purified ILC2s were trans-
ferred by intravenous injection 2 hr after N. brasiliensis injections.
E-alpha:Green Fluorescent Protein Fusion Protein
To assess the ability of ILC2s to present processed antigen, we cultured ILC2s
in the presence of 100 mg/ml E-alpha (Ea)-green fluorescent protein (GFP)
fusion protein for 20 hr. An Ea-specific antibody (cloneYAe) was used to detect
an Ea-derived peptide (Ea52-68) bound in the context of MHC (I-Ab) prior to
flow cytometric analysis.
Statistical Analysis
Graph Pad Prism was used to calculate the SEM when different numbers of
data sets existed in each experimental group. When data were normally
distributed and when two independent variables were being analyzed, a Krus-
kal-Wallis one-way ANOVAwith Bonferroni post-analysis was performed. In all
other instances, statistical differences between groups were calculated with
Student’s t test, with P < 0.05 considered significant.
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